<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02333838</url>
  </required_header>
  <id_info>
    <org_study_id>P130916</org_study_id>
    <secondary_id>2014-002109-39</secondary_id>
    <nct_id>NCT02333838</nct_id>
  </id_info>
  <brief_title>Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies</brief_title>
  <acronym>TBF-Cord</acronym>
  <official_title>Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Allogeneic cord blood stem cell transplantation is a potentially curative therapy for&#xD;
      patients with haematological malignancies. We have extensive experience with the use of Cord&#xD;
      Blood Transplantation (CBT) in patients with advanced myeloid malignancies. In adults&#xD;
      however, the 40% Non-Relapse Mortality (NRM) rate observed after CBT conditioned with a&#xD;
      myeloablative conditioning has encouraged the development of CBT with Reduced Intensity&#xD;
      Conditioning (RIC). Our previous national CBT protocol (the Minicord French protocol -&#xD;
      NCT00797758) showed that RIC CBT can reduce NRM, but relapse remains the main post-transplant&#xD;
      event (&gt;30% at one year). Thus, the development of reduced toxicity rather than RIC&#xD;
      conditioning for CBT is warranted in order to improve the outcome of such transplants by&#xD;
      limiting NRM and reducing relapse rate. The Fludarabine, ATG and intensified doses of IV&#xD;
      Busulfan (9.6 mg/Kg total dose) regimen is a well-established preparative regimen for&#xD;
      reduced-intensity/toxicity conditioning prior to allogeneic stem cell transplantation using&#xD;
      peripheral blood stem cells mobilized with G-CSF (ClinicalTrials.gov Identifier:&#xD;
      NCT00841724). However, such regimen is likely not sufficient to allow for CB cell&#xD;
      engraftment. Thiotepa is an alkylating and radio-mimetic agent with a large anti-tumor&#xD;
      activity including leukemic cells, the ability to cross the blood-brain barrier and to&#xD;
      improve engraftment of hematopoietic stem cells. This drug has been combined to usual&#xD;
      conditioning regimen without increasing the toxicity but improving the engraftment rate and&#xD;
      potentially reducing the relapse rate. Thus, in the context of adult CBT for high risk&#xD;
      myeloid malignancies, we propose to prospectively evaluate a reduced toxicity conditioning&#xD;
      based on the association of Thiotepa, Fludarabine, IV Busulfan and ATG with the objective to&#xD;
      achieve acceptable NRM rates, and to allow for improved anti-leukemic control based on the&#xD;
      cytotoxic component of the conditioning regimen itself, while waiting for the long term&#xD;
      immune-mediated disease control (GVL effect).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">May 2015</start_date>
  <completion_date type="Anticipated">May 2019</completion_date>
  <primary_completion_date type="Actual">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative incidence of NRM at 12 months after transplantation</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>Cumulative incidence of NRM at 12 months after transplantation : Safety and efficacy of the pre-transplant reduced toxicity conditioning regimen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of engraftment after transplantation</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>Incidence of neutrophil engraftment (day and proportion of patients reaching neutrophils &gt;0.5x109/L); and platelets recovery (day and proportion of patients reaching platelets &gt; 20 x 109 / L without transfusion) after transplantation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of acute GVHD</measure>
    <time_frame>6 months after transplantation</time_frame>
    <description>Incidence and severity of acute GVHD (diagnosed and graded as standard criteria)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and severity of chronic GVHD</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>Incidence and severity of chronic GVHD (diagnosed and graded as standard criteria detailed )</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of disease relapse at one year after transplantation</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>Incidence of disease relapse at one year after transplantation (relapse is defined on the basis of morphologica evidence of leukemic cells in the bone marrow or other sites)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months after transplantation</time_frame>
    <description>Evaluation of the quality of life (using a french translation of the FACT-BMT (version 4.0)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Leukemia, Myeloid</condition>
  <arm_group>
    <arm_group_label>Reduced toxicity conditioning regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Reduced toxicity conditioning regimen (thiotepa, busulfan, fludarabine and ATG) followed by unrelated cord blood allogeneic stem cell transplant for high risk myeloïd malignancies.&#xD;
The conditioning regimen will include:&#xD;
IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6)&#xD;
IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)&#xD;
IV Busulfan (Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3)&#xD;
IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)&#xD;
In patient with co-morbidities and/or older than 60 years, conditioning could be reduced after consulting the coordinator of the study:&#xD;
IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)&#xD;
IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)&#xD;
IV Busulfan (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)&#xD;
IV Anti-thymocyte globuline (Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Thiotepa</intervention_name>
    <description>IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6) or IV Thiotepa (5 mg/Kg/day for 2 days) (Day -6)</description>
    <arm_group_label>Reduced toxicity conditioning regimen</arm_group_label>
    <other_name>Thiotepa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Fludarabine</intervention_name>
    <description>IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)</description>
    <arm_group_label>Reduced toxicity conditioning regimen</arm_group_label>
    <other_name>Fludarabine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Busulfan</intervention_name>
    <description>(Busilvex 130 mg/m2/day for 3 days) (Day-5, -4 and -3) or (Busilvex 100 mg/m2/day for 3 days) (Day-5, -4 and -3)</description>
    <arm_group_label>Reduced toxicity conditioning regimen</arm_group_label>
    <other_name>Busulfan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Anti-thymocyte globuline</intervention_name>
    <description>(Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)</description>
    <arm_group_label>Reduced toxicity conditioning regimen</arm_group_label>
    <other_name>Anti-thymocyte globuline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years and ≤ 65 years&#xD;
&#xD;
          -  Patients diagnosed with one of the following diseases (validation of the indication of&#xD;
             allogeneic&#xD;
&#xD;
        HSCT with an alternative source of hematopoietic stem cells by centers' local RCP):&#xD;
&#xD;
          -  Acute myelogenous leukemia (AML) with intermediate or high risk features ((≥&#xD;
             intermediate risk 1) in CR1 or above according to centers' decision&#xD;
&#xD;
          -  Myelodysplastic syndromes with International Prognostic Scoring System (IPSS) score ³&#xD;
             2 (cf. appendix 3) or with symptomatic pancytopenia according to centers' decision&#xD;
&#xD;
          -  Chronic myelomonocytic leukemia (CMML)&#xD;
&#xD;
          -  Both MDS and CMML should have ≤ 10% blasts at transplantation&#xD;
&#xD;
          -  Absence of a matched sibling or unrelated donor (10/10 or 9/10 if mismatch on HLA Cw,&#xD;
             based on each center's donor selection criteria)&#xD;
&#xD;
          -  Cord blood units must be matched with patient at 4, 5, or 6/6 HLA loci, (class I&#xD;
             antigenic &amp; class II allelic level)with a minimum of 3.5 x 10^7 TNC/kg recipient body&#xD;
             weight in the pre-thawed fraction and with ≥2.5x10^7 TNC/kg for the richest cord blood&#xD;
             unit and ≥ 1.5x10^7 TNC/kg for the poorest blood unit in case of 2 cord blood units&#xD;
&#xD;
          -  Performance status : OMS score ≤ 1 (cf. appendix 5)&#xD;
&#xD;
          -  Cardiac function - left ventricular ejection fraction ≥ 45%.&#xD;
&#xD;
          -  Pulmonary function - diffusion capacity of at least 50% predicted.&#xD;
&#xD;
          -  Serum creatinine clearance 0 ml/min.&#xD;
&#xD;
          -  SGPT 4x normal , serum bilirubin &lt; 2 x normal.&#xD;
&#xD;
          -  Written informed consent.&#xD;
&#xD;
          -  Progestative treatment for women with persisting menstrual periods&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of a matched sibling or unrelated available donor (10/10 or 9/10 if mismatch&#xD;
             on HLA Cw in centers performing 9/10 HLA mismatched transplants)&#xD;
&#xD;
          -  Active infection at time of conditioning. In case of uncertainty regarding whether a&#xD;
             previous infection is resolved or not, this will be discussed with the PI on a case by&#xD;
             case basis.&#xD;
&#xD;
          -  Pregnancy in women with child bearing potential (pregnancy test performed within 2-4&#xD;
             weeks of study entry).&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Active CNS leukemia&#xD;
&#xD;
          -  Chronic or active Hepatitis B or Hepatitis C. If questions about liver health discuss&#xD;
             with PI and strongly consider liver biopsy.&#xD;
&#xD;
          -  Poor performance status : OMS score &gt; 1&#xD;
&#xD;
          -  Life expectancy is severely limited by concomitant illness and expected to be &lt;12&#xD;
             weeks.&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt;45%. Uncontrolled arrhythmias or symptomatic&#xD;
             cardiac disease.&#xD;
&#xD;
          -  Symptomatic pulmonary disease. FEV1, FVC and DLCO &lt;50% of expected corrected for&#xD;
             hemoglobin.&#xD;
&#xD;
          -  Serum creatinine clearance (Crockoft) below 50 mL/m per 1.73 m² or requiring dialysis&#xD;
&#xD;
          -  Vaccination with alive vaccine (virus or bacteria) &lt; 3 months&#xD;
&#xD;
          -  Fludarabine contra-indication&#xD;
&#xD;
          -  Thymoglobuline contra-indication&#xD;
&#xD;
          -  Patient under guardianship or curatorship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Thérèse RUBIO</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU Nancy</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital de Brabois, Hématologie Clinique et thérapie cellulaire</name>
      <address>
        <city>Vandoeuvre les Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Rocha V, Labopin M, Sanz G, Arcese W, Schwerdtfeger R, Bosi A, Jacobsen N, Ruutu T, de Lima M, Finke J, Frassoni F, Gluckman E; Acute Leukemia Working Party of European Blood and Marrow Transplant Group; Eurocord-Netcord Registry. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004 Nov 25;351(22):2276-85.</citation>
    <PMID>15564544</PMID>
  </reference>
  <reference>
    <citation>Arcese W, Rocha V, Labopin M, Sanz G, Iori AP, de Lima M, Sirvent A, Busca A, Asano S, Ionescu I, Wernet P, Gluckman E; Eurocord-Netcord Transplant group. Unrelated cord blood transplants in adults with hematologic malignancies. Haematologica. 2006 Feb;91(2):223-30.</citation>
    <PMID>16461307</PMID>
  </reference>
  <reference>
    <citation>Atsuta Y, Suzuki R, Nagamura-Inoue T, Taniguchi S, Takahashi S, Kai S, Sakamaki H, Kouzai Y, Kasai M, Fukuda T, Azuma H, Takanashi M, Okamoto S, Tsuchida M, Kawa K, Morishima Y, Kodera Y, Kato S; Japan Cord Blood Bank Network. Disease-specific analyses of unrelated cord blood transplantation compared with unrelated bone marrow transplantation in adult patients with acute leukemia. Blood. 2009 Feb 19;113(8):1631-8. doi: 10.1182/blood-2008-03-147041. Epub 2008 Dec 22.</citation>
    <PMID>19104080</PMID>
  </reference>
  <reference>
    <citation>Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, Sirvent A, Champlin RE, Chao N, Gee AP, Isola L, Laughlin MJ, Marks DI, Nabhan S, Ruggeri A, Soiffer R, Horowitz MM, Gluckman E, Wagner JE; Center for International Blood and Marrow Transplant Research; Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation); National Cord Blood Program of the New York Blood Center. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. Lancet Oncol. 2010 Jul;11(7):653-60. doi: 10.1016/S1470-2045(10)70127-3.</citation>
    <PMID>20558104</PMID>
  </reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>January 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cord Cell Transplantation</keyword>
  <keyword>High risk myeloid malignancies</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

